Recruiting

Genetically Modified T Cells to Treat Advanced Blood Cancer

Plain-English translation of NCT03271632 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Read our Multiple Myeloma research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new approach called Multi-CAR T Cell Therapy to treat multiple myeloma, a cancer of blood-forming cells. Researchers will take some of your immune cells, genetically modify them in the laboratory to recognize and attack myeloma cells, and then return the modified cells to your body. The goal is to see whether this treatment is safe and effective for patients whose myeloma has not responded to other therapies.

Multiple myeloma remains very difficult to treat, especially when patients relapse or don't respond to standard cancer drugs and transplants. This new treatment uses a cutting-edge approach to reprogram your own immune system to fight the cancer, offering hope for patients who have limited options left.

Do you qualify?

You likely qualify if…

you have been diagnosed with multiple myeloma that has either not gone into complete remission after at least 4 prior treatment regimens, or has relapsed after previous treatments
you are not a candidate for stem cell transplantation or have already had transplants that didn't work long-term
your disease has progressed within the last year or you have residual disease remaining after treatment
you have adequate kidney and liver function (creatinine below 2.5 mg/dl, liver enzymes less than 3 times normal, bilirubin below 2.0 mg/dl)
you have adequate veins to allow blood collection for the treatment process
your doctors expect you to survive at least 12 weeks

You likely don't qualify if…

you are pregnant or breastfeeding
you have an active, uncontrolled infection or active hepatitis B or C
you have HIV infection
you are currently taking systemic steroids (inhaled steroids are okay)
you have received CAR T cell therapy before, or you have another serious medical condition that would make participation unsafe

What participation looks like

You will undergo a procedure called leukapheresis, where doctors collect some of your white blood cells through a special catheter or IV line. These cells are then sent to the laboratory where they are genetically modified to recognize and attack myeloma cells. After the modified cells are ready, you will receive them back into your body as an infusion. The trial will track how you respond over time, monitoring whether the cells persist, function properly, and help control your myeloma.

AI-generated summary from trial data · Jul 9, 2026 · Not medical advice

Trial locations(1 site)

China

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong